529508-56-3

Usage

Uses

Used in Pharmaceutical Development:
CMPT is utilized as a key component in the development of novel pharmaceuticals, specifically for the treatment of cancer. Its mechanism of action involves the inhibition of enzymes that are crucial for the growth and proliferation of cancer cells, thereby offering a potential therapeutic strategy against various types of cancer.
Used in Cancer Treatment:
In the field of oncology, CMPT is employed as a chemotherapeutic agent, targeting the biochemical pathways that support the uncontrolled growth of cancer cells. Its potential to disrupt these pathways makes it a valuable asset in the fight against cancer, with the possibility of being used in combination with other treatments to enhance overall therapeutic efficacy.
Used in Antibacterial and Antiviral Research:
Beyond its cancer-fighting properties, CMPT has also been investigated for its antibacterial and antiviral capabilities. Its unique chemical structure allows it to interact with microbial and viral components, potentially inhibiting their replication and spread. This dual functionality positions CMPT as a versatile compound with broad-spectrum applications in infectious disease management.
Used in Drug Discovery and Design:
CMPT's unique structure and chemical properties make it an attractive candidate for further research and development in the field of drug discovery and design. Its potential applications extend beyond cancer and infectious diseases, as its properties may be harnessed to develop new drugs for a variety of therapeutic areas, including but not limited to cardiovascular, neurological, and metabolic disorders.

Upstream product

• 529508-54-1 5-methylpyrrolo[2,1-f][1,2,4]triazin-4(3H)-one 
• 5448-16-8 3-methyl-1H-pyrrole-2,4-dicarboxylic acid diethyl ester 
• 427878-69-1 1-amino-3-methyl-1H-pyrrole-2,4-dicarboxylic acid diethyl ester 
• 427878-70-4 ethyl 4-hydroxy-5-methylpyrrolo[2,1-f ][1,2,4]-triazine-6-carboxylate 
• 310435-15-5 C₈H₇N₃O₃ 
• 529508-54-1 C₇H₇N₃O 
• 3284-47-7 ethyl 3-methyl-1H-pyrrole-2-carboxylate 
• 1392140-56-5 ethyl 1-amino-3-methyl-1H-pyrrole-2-carboxylate 
• 310435-15-5 5-methyl-4-oxo-3,4-dihydro-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid 
• 310431-29-9 5-methyl-4-oxo-3,4-dihydro-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid methyl ester 

Downstream Products

• 529508-57-4 5-(bromomethyl)-4-chloropyrrolo[2,1-f][1,2,4]triazine 
• 859855-15-5 4-(3-methoxyphenylamino)pyrrolo[2,1-f][1,2,4]triazin-5-ylmethyl triethylammonium bromide 
• 888720-34-1 4-(2-fluoro-4-nitrophenoxy)-5-methylpyrrolo[2,1-f][1,2,4]triazine 
• 859205-93-9 (S)-2-{4-[3-chloro-4-(3-fluoro-benzyloxy)-5 phenylamino]-pyrrolo[2,1-f][1,2,4]triazin-5-ylmethoxy methyl}-morpholine-4-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

PYRROLO[2,1-F][1,2,4]TRIAZINE DERIVATIVES SERVING AS SELECTIVE HER2 INHIBITORS AND APPLICATION THEREOF

The present invention relates to a group of pyrrolo[2, 1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and an application thereof in the preparation of a drug that serves as an HER2 inhibitor. Specifically, the present invention relates to a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.

PYRROLOTRIAZINE KINASE INHIBITORS

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

Development of a practical synthesis of a functionalized pyrrolo[2,1-f][1,2,4]triazine nucleus

Functionalized pyrrolotriazine 1b is a key heterocyclic building block in the synthesis of BMS-690514, a potent anticancer agent. Described herein are our development activities that led to the efficient preparation of 1b on a large scale. The key transformations include a selective C-alkylation of an oxalacetate salt with a hydrazonyl bromide to form a 2-hydrazonoethyl-3- oxosuccinate, followed by cyclodehydration to an aminopyrrole. Subsequent deprotection and condensation with formamidine afforded the pyrrolotriazine scaffold. Further elaboration of this core provided the desired pyrrolotriazinyl amine.

SYNTHETIC PROCESS

The present invention provides a process for preparing compounds of formula (IV), or a pharmaceutically acceptable salt thereof. The compounds prepared by the process of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER

C-5 Modified indazolylpyrrolotriazines

The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.